Clinical Study Data Request Registered Users, Please Login

Proposal 628

Title of the Proposed Research

Predictive and Prognostic Value of Blood Cell Ratios in Patients with Metastatic Renal Cell Carcinoma Treated with Pazopanib

Lead Researcher

Arnoud J. Templeton, MD


Princess Margaret Cancer Centre
Department of Medicine, University of Toronto
Toronto, Ontario, CA

Data Sharing Agreement Date

22 January 2014

Lay Summary

Many patients with advanced kidney cancer wish to receive information about the likelihood to respond to treatments like pazopanib and about their life expectancy. Groups with different expectation of survival are based on clinical and disease-related factors and research to improve their accuracy is an ongoing need. We will investigate the predictive value of a readily available and inexpensive marker, based on blood counts determined in routine practice. It is hoped to establish a marker that is helpful for treating physicians and their patients when discussing the chance of response to pazopanib outcome of advanced kidney cancer

Study Data Provided

Study VEG105192: A Randomised, Double-blind, Placebo controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or Metastatic Renal Cell Carcinoma
Study VEG102616: A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma

Funding Source of Research

This research will be funded through grants received by Dr. J. Knox (Princess Margaret Cancer Centre, Toronto, Canada)

Potential Conflicts of Interest

Lead Researcher: None
Researcher 1: None
Researcher 2: Advisory board Roche
Researcher 3: Research Funding - Novartis; Pfizer
Dr. Knox is the co-chair of the RECORD-3 study ( NCT00903175)

Statistical Analysis Plan

This will be added after the research is published.

Publication Citation